Oleanolic acid modulates multiple intracellular targets to inhibit colorectal cancer growth

Li,Li; Wei,Lihui; Shen,Aling; Chu,Jianfeng; Lin,Jiumao; Peng,Jun

doi:10.3892/ijo.2015.3198

Oleanolic acid modulates multiple intracellular targets to inhibit colorectal cancer growth

Authors:
- Li Li
- Lihui Wei
- Aling Shen
- Jianfeng Chu
- Jiumao Lin
- Jun Peng
View Affiliations

Affiliations: Department of Disease Prevention and Healthcare, Fujian Provincial Hospital, Fuzhou, Fujian 350001, P.R. China, Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Minhou Shangjie, Fuzhou, Fujian 350122, P.R. China
Published online on: October 12, 2015 https://doi.org/10.3892/ijo.2015.3198
Pages: 2247-2254

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Due to drug resistance and unacceptable cytotoxicity of most currently-used cancer chemotherapies, naturally occurring products have gained attention in the field of anticancer treatment. Oleanolic acid (OA) is a natural pentacyclic triterpenoic acid and a principal active compound in many medicinal herbs that have long been used to clinically treat various types of human malignancies. Using a colorectal cancer (CRC) mouse xenograft model and the cell line HT-29, we evaluated the effect of OA on tumor growth in vivo and in vitro, and investigated the underlying molecular mechanisms in the present study. We found that OA significantly inhibited tumor growth in volume and weight in CRC xenograft mice. In addition, OA treatment led to the induction of apoptosis and inhibition of cell proliferation. OA significantly reduced the expression of Bcl-2, Cyclin D1 and CKD4, whereas Bax and p21 expression was profoundly increased after OA treatment. Furthermore, OA significantly suppressed the activation of Akt, p70S6K and MAPK signalings, but promoted p53 pathway activation. Collectively, findings from this study suggest that OA possesses a broad range of anticancer effects via modulation of multiple intracellular targets.

View Figures

View References

1	Siegel R, Desantis C and Jemal A: Colorectal cancer statistics, 2014. CA Cancer J Clin. 64:104–117. 2014. View Article : Google Scholar : PubMed/NCBI
2	DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Alteri R, Robbins AS and Jemal A: Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 64:252–271. 2014. View Article : Google Scholar : PubMed/NCBI
3	Clarke RB: p27^KIP1 phosphorylation by PKB/Akt leads to poor breast cancer prognosis. Breast Cancer Res. 5:162–163. 2003. View Article : Google Scholar :
4	Chang F, Lee JT, Navolanic PM, Steelman LS, Shelton JG, Blalock WL, Franklin RA and McCubrey JA: Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: A target for cancer chemotherapy. Leukemia. 17:590–603. 2003. View Article : Google Scholar : PubMed/NCBI
5	Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J and Greenberg ME: Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 96:857–868. 1999. View Article : Google Scholar : PubMed/NCBI
6	Pratheeshkumar P, Budhraja A, Son YO, Wang X, Zhang Z, Ding S, Wang L, Hitron A, Lee JC, Xu M, et al: Quercetin inhibits angiogenesis mediated human prostate tumor growth by targeting VEGFR-2 regulated AKT/mTOR/P70S6K signaling pathways. PLoS One. 7:e475162012. View Article : Google Scholar
7	Li W, Tan D, Zhang Z, Liang JJ and Brown RE: Activation of Akt-mTOR-p70S6K pathway in angiogenesis in hepatocellular carcinoma. Oncol Rep. 20:713–719. 2008.PubMed/NCBI
8	Roberts PJ and Der CJ: Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 26:3291–3310. 2007. View Article : Google Scholar : PubMed/NCBI
9	Schwartsmann G, Di Leone LP, Dal Pizzol F and Roesler R: MAPK pathway activation in colorectal cancer: A therapeutic opportunity for GRP receptor antagonists. Lancet Oncol. 6:444–445. 2005. View Article : Google Scholar : PubMed/NCBI
10	Fang JY and Richardson BC: The MAPK signalling pathways and colorectal cancer. Lancet Oncol. 6:322–327. 2005. View Article : Google Scholar : PubMed/NCBI
11	Quartuccio SM, Lantvit DD, Bosland MC and Burdette JE: Conditional inactivation of p53 in mouse ovarian surface epithelium does not alter MIS driven Smad2-dominant negative epithelium-lined inclusion cysts or teratomas. PLoS One. 8:e650672013. View Article : Google Scholar : PubMed/NCBI
12	Van Cutsem E and Costa F: Progress in the adjuvant treatment of colon cancer: Has it influenced clinical practice? JAMA. 294:2758–2760. 2005. View Article : Google Scholar : PubMed/NCBI
13	Longley DB, Allen WL and Johnston PG: Drug resistance, predictive markers and pharmacogenomics in colorectal cancer. Biochim Biophys Acta. 1766:184–196. 2006.PubMed/NCBI
14	Lippman SM: The dilemma and promise of cancer chemoprevention. Nat Clin Pract Oncol. 3:5232006. View Article : Google Scholar : PubMed/NCBI
15	Ma X and Wang Z: Anticancer drug discovery in the future: An evolutionary perspective. Drug Discov Today. 14:1136–1142. 2009. View Article : Google Scholar : PubMed/NCBI
16	Gordaliza M: Natural products as leads to anticancer drugs. Clin Transl Oncol. 9:767–776. 2007. View Article : Google Scholar : PubMed/NCBI
17	Newman DJ, Cragg GM and Snader KM: The influence of natural products upon drug discovery. Nat Prod Rep. 17:215–234. 2000. View Article : Google Scholar : PubMed/NCBI
18	Lin J, Wei L, Shen A, Cai Q, Xu W, Li H, Zhan Y, Hong Z and Peng J: Hedyotis diffusa Willd extract suppresses Sonic hedgehog signaling leading to the inhibition of colorectal cancer angiogenesis. Int J Oncol. 42:651–656. 2013. View Article : Google Scholar : PubMed/NCBI
19	Cai Q, Lin J, Wei L, Zhang L, Wang L, Zhan Y, Zeng J, Xu W, Shen A, Hong Z, et al: Hedyotis diffusa Willd inhibits colorectal cancer growth in vivo via inhibition of STAT3 signaling pathway. Int J Mol Sci. 13:6117–6128. 2012. View Article : Google Scholar : PubMed/NCBI
20	Lin J, Chen Y, Wei L, Chen X, Xu W, Hong Z, Sferra TJ and Peng J: Hedyotis Diffusa Willd extract induces apoptosis via activation of the mitochondrion-dependent pathway in human colon carcinoma cells. Int J Oncol. 37:1331–1338. 2010.PubMed/NCBI
21	Lin J, Chen Y, Cai Q, Wei L, Zhan Y, Shen A, Sferra TJ and Peng J: Scutellaria Barbata D Don inhibits colorectal cancer growth via suppression of multiple signaling pathways. Integr Cancer Ther. 13:240–248. 2013. View Article : Google Scholar : PubMed/NCBI
22	Wei L, Lin J, Wu G, Xu W, Li H, Hong Z and Peng J: Scutellaria barbata D. Don induces G1/S arrest via modulation of p53 and Akt pathways in human colon carcinoma cells. Oncol Rep. 29:1623–1628. 2013.PubMed/NCBI
23	Wei L, Lin J, Xu W, Cai Q, Shen A, Hong Z and Peng J: Scutellaria barbata D. Don inhibits tumor angiogenesis via suppression of Hedgehog pathway in a mouse model of colorectal cancer. Int J Mol Sci. 13:9419–9430. 2012. View Article : Google Scholar : PubMed/NCBI
24	Chen L, Liu L, Ye L, Shen A, Chen Y, Sferra TJ and Peng J: Patrinia scabiosaefolia inhibits colorectal cancer growth through suppression of tumor angiogenesis. Oncol Rep. 30:1439–1443. 2013.PubMed/NCBI
25	Liu L, Shen A, Chen Y, Wei L, Lin J, Sferra TJ, Hong Z and Peng J: Patrinia scabiosaefolia induces mitochondrial-dependent apoptosis in a mouse model of colorectal cancer. Oncol Rep. 30:897–903. 2013.PubMed/NCBI
26	Peng J, Chen Y, Lin J, Zhuang Q, Xu W, Hong Z and Sferra TJ: Patrinia scabiosaefolia extract suppresses proliferation and promotes apoptosis by inhibiting the STAT3 pathway in human multiple myeloma cells. Mol Med Rep. 4:313–318. 2011.PubMed/NCBI
27	Liu J: Oleanolic acid and ursolic acid: Research perspectives. J Ethnopharmacol. 100:92–94. 2005. View Article : Google Scholar : PubMed/NCBI
28	Wang X, Bai H, Zhang X, Liu J, Cao P, Liao N, Zhang W, Wang Z and Hai C: Inhibitory effect of oleanolic acid on hepatocellular carcinoma via ERK-p53-mediated cell cycle arrest and mitochondrial-dependent apoptosis. Carcinogenesis. 34:1323–1330. 2013. View Article : Google Scholar : PubMed/NCBI
29	Lúcio KA, Rocha GG, Monção-Ribeiro LC, Fernandes J, Takiya CM and Gattass CR: Oleanolic acid initiates apoptosis in non-small cell lung cancer cell lines and reduces metastasis of a B16F10 melanoma model in vivo. PLoS One. 6:e285962011. View Article : Google Scholar : PubMed/NCBI
30	Evan GI and Vousden KH: Proliferation, cell cycle and apoptosis in cancer. Nature. 411:342–348. 2001. View Article : Google Scholar : PubMed/NCBI
31	Adams JM and Cory S: The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene. 26:1324–1337. 2007. View Article : Google Scholar : PubMed/NCBI
32	Chen Y, Robles AI, Martinez LA, Liu F, Gimenez-Conti IB and Conti CJ: Expression of G1 cyclins, cyclin-dependent kinases, and cyclin-dependent kinase inhibitors in androgen-induced prostate proliferation in castrated rats. Cell Growth Differ. 7:1571–1578. 1996.PubMed/NCBI
33	Graña X and Reddy EP: Cell cycle control in mammalian cells: Role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene. 11:211–219. 1995.PubMed/NCBI
34	Chung DC, Brown SB, Graeme-Cook F, Seto M, Warshaw AL, Jensen RT and Arnold A: Overexpression of cyclin D1 occurs frequently in human pancreatic endocrine tumors. J Clin Endocrinol Metab. 85:4373–4378. 2000.PubMed/NCBI
35	Keum JS, Kong G, Yang SC, Shin DH, Park SS, Lee JH and Lee JD: Cyclin D1 overexpression is an indicator of poor prognosis in resectable non-small cell lung cancer. Br J Cancer. 81:127–132. 1999. View Article : Google Scholar : PubMed/NCBI
36	Harper JW, Adami GR, Wei N, Keyomarsi K and Elledge SJ: The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 75:805–816. 1993. View Article : Google Scholar : PubMed/NCBI
37	Adams JM and Cory S: Bcl-2-regulated apoptosis: Mechanism and therapeutic potential. Curr Opin Immunol. 19:488–496. 2007. View Article : Google Scholar : PubMed/NCBI
38	Peng J, Ding J, Tan C, Baggenstoss B, Zhang Z, Lapolla SM and Lin J: Oligomerization of membrane-bound Bcl-2 is involved in its pore formation induced by tBid. Apoptosis. 14:1145–1153. 2009. View Article : Google Scholar : PubMed/NCBI
39	Peng J, Tan C, Roberts GJ, Nikolaeva O, Zhang Z, Lapolla SM, Primorac S, Andrews DW and Lin J: tBid elicits a conformational alteration in membrane-bound Bcl-2 such that it inhibits Bax pore formation. J Biol Chem. 281:35802–35811. 2006. View Article : Google Scholar : PubMed/NCBI
40	Yip KW and Reed JC: Bcl-2 family proteins and cancer. Oncogene. 27:6398–6406. 2008. View Article : Google Scholar : PubMed/NCBI